This section provides guidance to aid the development of intellectual property strategies.
GNL36: Placing medical devices on the UK market after the end of Brexit transition
GNL35: What the UK-EU Trade and Cooperation Agreement means for pharma and medical device companies
GNL 30: Regulating life sciences products in the transition period
GNL 29: Biosimilars and naming duplicates
GNL 27: IPEC Cost effective and quick procedure for IP disputes
GNL 25: Data and market exclusivity: additional protections
GNL 24: Data and market exclusivity: what it is and how long it lasts
GNL 20: Paediatric extensions
GNL 7: Infringement – Supplementary Protection Certificates
GNL 6: Introduction to Patent Infringement
